Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.
(2014) In Clinical and Experimental Rheumatology 32(6). p.883-890- Abstract
- Patients with rheumatoid arthritis (RA), particularly those with severe disease, have increased risk of cardiovascular disease (CVD). Previous studies suggest that endothelial cell activation may contribute to this co-morbidity, and that treatment with tumour necrosis factor (TNF) inhibitors could reduce the risk of CVD in these patients. The aim of this study was to investigate endothelial cell activation markers in muscle tissue of patients after adalimumab treatment.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4737579
- author
- Bergström, Ulf LU ; Grundtman, Cecilia ; Lundberg, Ingrid E ; Jacobsson, Lennart LU ; Nilsson, Käth and Turesson, Carl LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical and Experimental Rheumatology
- volume
- 32
- issue
- 6
- pages
- 883 - 890
- publisher
- Pacini
- external identifiers
-
- pmid:25287961
- wos:000347869700007
- scopus:84925287226
- ISSN
- 1593-098X
- language
- English
- LU publication?
- yes
- id
- fe9019cc-187a-435e-ad14-d19370a61eba (old id 4737579)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25287961?dopt=Abstract
- date added to LUP
- 2016-04-01 11:16:48
- date last changed
- 2022-02-18 01:34:02
@article{fe9019cc-187a-435e-ad14-d19370a61eba, abstract = {{Patients with rheumatoid arthritis (RA), particularly those with severe disease, have increased risk of cardiovascular disease (CVD). Previous studies suggest that endothelial cell activation may contribute to this co-morbidity, and that treatment with tumour necrosis factor (TNF) inhibitors could reduce the risk of CVD in these patients. The aim of this study was to investigate endothelial cell activation markers in muscle tissue of patients after adalimumab treatment.}}, author = {{Bergström, Ulf and Grundtman, Cecilia and Lundberg, Ingrid E and Jacobsson, Lennart and Nilsson, Käth and Turesson, Carl}}, issn = {{1593-098X}}, language = {{eng}}, number = {{6}}, pages = {{883--890}}, publisher = {{Pacini}}, series = {{Clinical and Experimental Rheumatology}}, title = {{Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.}}, url = {{http://www.ncbi.nlm.nih.gov/pubmed/25287961?dopt=Abstract}}, volume = {{32}}, year = {{2014}}, }